Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$423.65 USD

423.65
553,842

-6.17 (-1.44%)

Updated Nov 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego

by Zacks Equity Research

PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here's How

by Zacks Equity Research

PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.

Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers

by Zacks Equity Research

The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY

by Zacks Equity Research

Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.

Here's Why You Should Retain Catalent (CTLT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment

by Zacks Equity Research

Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW

by Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.

Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients

by Zacks Equity Research

Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.

Here's Why You Should Retain CONMED (CNMD) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics

by Zacks Equity Research

NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.

NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone

by Zacks Equity Research

NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.

Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (IDXX) Outperforming Other Medical Stocks This Year?

Reasons to Hold on to AMN Healthcare (AMN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

SmileDirectClub (SDC) Struggles With New Markets, High Debt

by Zacks Equity Research

SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.

Stryker (SYK) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.

TransMedics (TMDX) Receives FDA Nod for OCS Heart System

by Zacks Equity Research

TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.

Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

by Zacks Equity Research

Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

by Zacks Equity Research

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Omnicell (OMCL) Opens New Software Development Center in India

by Zacks Equity Research

Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.

Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

by Zacks Equity Research

Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

Here's Why You Should Add STERIS (STE) to Your Portfolio Now

by Zacks Equity Research

STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.